The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.

During the last 5 years, major advances have been made in our understanding of the pathogenesis of human immunodeficiency virus (HIV) disease and in the development of new potent antiviral agents. With regard to HIV pathogenesis, several recent observations have not only changed our perspectives of HIV disease, but have been critical for the design of therapeutic strategies.

During the early years of the AIDS epidemic, thousands of Americans became infected with HIV through the nation's blood supply. Because little reliable information existed at the time AIDS first began showing up in hemophiliacs and in others who had received transfusions, experts disagreed about whether blood and blood products could transmit the disease. During this period of great uncertainty, decision-making regarding the blood supply became increasingly difficult and fraught with risk. This volume provides a balanced inquiry into the blood safety controversy, which involves private sexual practices, personal tragedy for the victims of HIV/AIDS, and public confidence in America's blood services system. The book focuses on critical decisions as information about the danger to the blood supply emerged. The committee draws conclusions about what was doneâ€"and recommends what should be done to produce better outcomes in the face of future threats to blood safety. The committee frames its analysis around four critical area: Product treatmentâ€"Could effective methods for inactivating HIV in blood have been introduced sooner? Donor screening and referralâ€"including a review of screening to exlude high-risk individuals. Regulations and recall of contaminated bloodâ€"analyzing decisions by federal agencies and the private sector. Risk communicationâ€"examining whether infections could have been averted by better communication of the risks.

This authoritative handbook covers all aspects of immunosenescence, with contributions from experts in the research and clinical areas. It examines methods and models for studying immunosenescence; genetics; mechanisms including receptors and signal transduction; clinical relevance in disease states including infections, autoimmunity, cancer, metabolic syndrome, neurodegenerative diseases, frailty and osteoporosis; and much more.

Infection with the human immunodeficiency virus is characterized by the destruction of the host immune system as also reflected by a progressive loss of CD4-positive T-cells. This finally results in the host's incapacity to deal with opportunistic infections and the immune surveillance of tumors, a clinical status known as the Acquired Immunodeficiency Syndrome (AIDS). The book AIDS Pathogenesis provides the reader with a complete overview of the clinical course of HIV-1 infection. It describes the clinical aspects of primary infection, the different clinical outcomes of HIV-1 infection, and strategies for anti-viral treatment. In addition, more fundamental aspects of HIV-1 infection are reviewed. These include the biology of the virus and the novel insights in AIDS pathogenesis. Not only is the significance of an HIV-specific cellular and humoral immune response discussed, but also the possible incapacity of the adult human host to deal with T-cell destruction. Finally, the book discusses the currently used laboratory markers that allow for monitoring of the clinical course of infection.

Biomaterials for Clinical Applications is organized according to the World Health Organization’s report of the top 11 causes of death worldwide, and lays out opportunities for both biomaterials scientists and physicians to tackle each of these leading contributors to mortality. The introductory chapter discusses the global burden of disease. Each of the subsequent eleven chapters focuses on a specific disease process, beginning with the leading cause of death worldwide, cardiovascular disease. The chapters start with describing diseases where clinical needs are most pressing, and then envisions how biomaterials can be designed to address these needs, instead of the more technologically centered approached favored by most books in the field. This book, then, should appeal to chemical engineers and bioengineers who are designing new biomaterials for drug delivery and vaccine delivery, as well as tissue engineering.